ятипалої кишки, у зв'язку з чим слід проводити профілактику ускладнень з боку ШКТ. Єдиним препаратом АСК, який всмоктується в шлунку, а не в кишечнику, але при цьому дозволяє знизити ризик ураження ШКТ [29], є Кардиомагнил, що містить антацид (гідроксид магнію). Кардиомагнил поєднує в собі переваги простий АСК (швидке і повне всмоктування в шлунку, швидкий початок дії, більш прогнозований антитромботичний ефект) з протективного дією гідроксиду магнію на слизову ШКТ.
Список літератури
1. Chan F.K., Graham D.Y. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment / / Aliment. Pharmacol. Ther. 2004. Vol. 19. P. 1051-1061.
2. Antithrombotic Trialists 'Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients / / BMJ. 2002. Vol. 324. P. 71-86.
3. Peto R., Gray R., Collins R. et al. Randomised trial of prophylactic daily aspirin in British male doctors / / BMJ. 1988. Vol. 296. P. 313-316.
4. Steering Committee of the Physicians 'Health Study Research Group. Final report on the aspirin component of the ongoing Physicians 'Health Study / / N. Engl. J. Med. 1989. Vol. 321. P. 129-135.
5. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk / / Lancet. 1998. Vol. 351. P. 233-241.
6. Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial / / Lancet. 1998. Vol. 351. P. 1755-1762.
7. Zanchetti A., Hansson L., Dahlof B. et al. on behalf of the HOT Study Group. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk / / J. Hypertens. 2002. Vol. 20. P. 2301-2307.
8. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice / / Lancet. 2001. Vol. 357. P. 89-95.
9. Ridker P.M., Cook N.R., Lee I.M. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women / / N. Engl. J. Med. 2005. Vol. 352. P. 1293-1304.
10. Antithrombotic Trialists '(ATT) Collaboration; Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials / / Lancet. 2009. Vol. 373. P. 1849-1860.
11. Berger JS, Roncaglioni MC, Avanzini F. et al. Aspirin for th...
